Results 81 to 90 of about 1,671,061 (305)
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu +9 more
wiley +1 more source
Key questions about the checkpoint blockade-are microRNAs an answer?
The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early ...
Mihnea Dragomir +3 more
doaj +1 more source
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso +5 more
wiley +1 more source
Immune checkpoint blockade therapy [PDF]
Immune checkpoints are accessory molecules that either promote or inhibit T-cell activation. Two inhibitory molecules, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), got high attention, as inhibition of CTLA-4 or PD-1 signaling provides the first immune therapy that significantly improves the survival of patients ...
Thomas, Wieder +3 more
openaire +2 more sources
The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj +1 more source
The role of immune checkpoint inhibitors in prostate cancer [PDF]
Introduction Prostate cancer (PC) is the most commonly diagnosed malignant tumour and the third cause of cancer deaths among men in Europe. The treatment of early-stage PC is very effective and in many cases allows achievement of a complete cure, whereas
Marek Hus +9 more
core +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Corticosteroids and immune checkpoint blockade
Novel immunotherapies acting through immune checkpoint blockade to stimulate the immune response have demonstrated promising outcomes in advanced malignancies [1]. As a result, novel cancer immunotherapy was named a scientific breakthrough of the year in 2013 by Science.
Le, Min +2 more
openaire +2 more sources
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
Vaccination-enabled immune readiness for checkpoint blockade
Immune checkpoint blockade has transformed cancer therapy by demonstrating that durable tumour control can be achieved through immune modulation rather than direct cytotoxicity.
Jhommara Bautista +1 more
doaj +1 more source

